{"id":470805,"date":"2021-04-05T09:03:30","date_gmt":"2021-04-05T13:03:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470805"},"modified":"2021-04-05T09:03:30","modified_gmt":"2021-04-05T13:03:30","slug":"sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/","title":{"rendered":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, April  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r1dzBtuObHvOr-1XaZyy9cxXzXeCMtXqdveK8zV5bgvl69kpSdSyBrs8OWccO_R2gzwFEvPvlKUMwbbX8dusd9myWm2YKj7HAIUNOH8TLa4hqfUdXJgs-TyldwA6-AP2VTnMijCVtKAqr7scJsG0-poFe_xsfHhtphc-8kZDVVtup6t1Inc6CArBCAVawTyV54CgS62vj_6Y03IPkNQ413VnpG_BMxk1k7vpsCj0hLpYhGF4OhTQmWYNDXWdixkuIzC6lns1HbBzd0UsbBzTmA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SEngine Precision Medicine<\/u><\/strong><\/a>, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, announced today that the PARIS\u00ae\u00a0Test was utilized in a study to identify novel drug targets and combinations to combat ovarian clear cell carcinoma (OCCC). The study, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IEDiBtuAEUrjxyV2IV1r1Nr4aCIpNzMvuxgS9XLGNMa_Es9y7XZHLR0vgsIxThNLqo4gNN-h_QD1PZE8uJWR5nKry7jf4HDblium0XkcB2z1Q_7lMyyvrl0CXWrUhNq9r3BtOz1TXM4jbH3yy3yf-n0HlJtDjbqODDW3fttzlV1BiW2Joz49dVMgJSKGN9u1F2noGTOWXpYkgAq0_ycPnHcUahVG9AdqH_pUL1kx9hSgIccqWbYucafl8mva6ox5ffcSBuh3npynNndzy0NBPppgxbteJgdWqYukQH4zkTzFK4n5AqBMiPvSW3yO7obh\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">\u201cTargeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma,\u201d<\/a> was recently published in\u00a0American Association for Cancer Research\u2019s <em>Molecular Cancer Therapeutics<\/em>\u00a0and was co-authored by researchers from the Fred Hutchinson Cancer Research Center, SEngine Precision Medicine, Weill Cornell Medicine, and the University of Washington.<\/p>\n<p>Ovarian clear cell carcinoma, a relatively uncommon subtype of ovarian cancer, has historically been treated with the same platinum-based chemotherapies as patients with high grade serous carcinoma. However, clear cell carcinoma patients typically display a poorer response to chemotherapies, which leads to lower overall survival for these patients. In this study, researchers identified BET proteins BRD2 and BRD3 as novel targets against ovarian clear cell carcinoma, which could lead to more effective targeted therapies for this subtype. Additional drug sensitivity screening identified the combination of BET protein and PI3K-AKT pathway inhibitors as a promising therapeutic path for further investigation. SEngine\u2019s PARIS\u00ae Test, a high-throughput drug sensitivity assay using patient-derived tumor organoids, was utilized in this study to validate the drug-response findings on ovarian cancer cell models. In addition to the PARIS\u00ae Test already being utilized as a clinical tool guiding oncologists\u2019 treatment decisions for patients with ovarian cancer, this study demonstrates the power of SEngine\u2019s functional drug sensitivity assay to identify novel therapeutic targets and drug synergies to combat hard-to-treat ovarian cancers.<\/p>\n<p>&#8220;We are excited to share these new findings that identified two novel BET proteins as candidate therapeutic targets for OCCC and suggest a potential drug combination therapeutic strategy for OCCC,\u201d said Shogo Shigeta, MD, PhD, current Research Associate in the department of gynecology at the Tohoku University Graduate School of Medicine and lead author of the study. \u201cThe validation of our study with organoids derived from patient samples will help enable rapid clinical translation.&#8221;<\/p>\n<p>\u201cIn this study, SEngine\u2019s PARIS\u00ae Test was applied to patient derived tumor cells to identify new therapeutic strategies for hard-to-treat cancers. This is yet another example of the benefit that functional testing brings to oncologists seeking novel treatment options,\u201d commented Carla Grandori, MD, PhD, co-founder and Chief Executive Officer of SEngine Precision Medicine.<\/p>\n<p>\n        <strong>About PARIS\u00ae Test<\/strong>\u00a0<br \/>The PARIS\u00ae\u00a0Test is based on the capability to propagate patient-specific cancer\u00a0cells\u00a0as organoids\u00a0outside the body\u00a0and is applicable to all solid tumors\u00a0including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown\u00a0in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics.\u00a0For cancers\u00a0where\u00a0a treatment\u00a0path is not clear, such as\u00a0many metastatic and recurrent cancers,\u00a0the PARIS\u00ae Test provides crucial information to\u00a0treating physicians\u00a0to\u00a0match the right drug to the right patient.<\/p>\n<p>\n        <strong>About SEngine Precision Medicine<\/strong><br \/>\n        <br \/>SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells.\u00a0As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&amp;D in diagnostics and drug discovery. The Company is commercializing the PARIS\u00ae Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine\u2019s CLIA certified PARIS\u00ae Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical \/ pharma companies leveraging its precision oncology platform.<\/p>\n<p>Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zpIVlwGH1F5Uk3T2Dct2issJ7yzXiX9ecSTDEUHwiwSfwUKiZYm-nr7-j6gneoVwemMD7ZLpd1yNM3-BTkhOrEnFpAiTon9MQnthVuLz40k=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SengineMedicine.com<\/u><\/strong><\/a>\u00a0and follow the latest news from SEngine on Twitter at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mt7O_wHTYm6OEeRCNOlVLLiIjYMwHHWcj0PRkl4NWMbHsq0vTrnNx-f3V_xxyxcOpLgN7LKQ82nOcvto_dcpPFNzAsJqwrXbtfoaUAuN1bA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>@SEngineMedicine<\/u><\/strong><\/a>\u00a0and on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xmp6txXHTm27lmcggqTNGOBERIvg7dc6QW05OWv9EnaCMgdehA-q4PjlYZUMsquBTeiN5E1Frg7A-cqYZSzN-STQOtSS7anNXop8wDjt2_ZcN_C4DPcG11BecvLt0Sst\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>LinkedIn<\/u><\/strong><\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Stephanie Carrington<br \/><strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TCA8fWwZbpS4Lc3FesaStR1V7SOIEMyCPek5cneVgXFC-tKUqPo4_VqS4eyD2v-bWIRi4uIow8TnPMp7L-1mw6kDA8jXL7IpGdueFFWfRv1gw8auYbLuWJf9_opVGxMcp7FxgAlnu9fd_vOF_V5VPw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">stephanie.carrington@westwicke.com<br \/><\/a><\/u><\/strong>646-277-1282\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/509304ae-a4e6-4d02-a82b-0c343b33339a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, announced today that the PARIS\u00ae\u00a0Test was utilized in a study to identify novel drug targets and combinations to combat ovarian clear cell carcinoma (OCCC). The study, \u201cTargeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma,\u201d was recently published in\u00a0American Association for Cancer Research\u2019s Molecular Cancer Therapeutics\u00a0and was co-authored by researchers from the Fred Hutchinson Cancer Research Center, SEngine Precision Medicine, Weill Cornell Medicine, and the University of Washington. Ovarian clear cell carcinoma, a relatively uncommon subtype of ovarian cancer, has historically been treated with the same &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470805","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, announced today that the PARIS\u00ae\u00a0Test was utilized in a study to identify novel drug targets and combinations to combat ovarian clear cell carcinoma (OCCC). The study, \u201cTargeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma,\u201d was recently published in\u00a0American Association for Cancer Research\u2019s Molecular Cancer Therapeutics\u00a0and was co-authored by researchers from the Fred Hutchinson Cancer Research Center, SEngine Precision Medicine, Weill Cornell Medicine, and the University of Washington. Ovarian clear cell carcinoma, a relatively uncommon subtype of ovarian cancer, has historically been treated with the same &hellip; Continue reading &quot;SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T13:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics\",\"datePublished\":\"2021-04-05T13:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/\"},\"wordCount\":672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/\",\"name\":\"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\",\"datePublished\":\"2021-04-05T13:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk","og_description":"SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, announced today that the PARIS\u00ae\u00a0Test was utilized in a study to identify novel drug targets and combinations to combat ovarian clear cell carcinoma (OCCC). The study, \u201cTargeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma,\u201d was recently published in\u00a0American Association for Cancer Research\u2019s Molecular Cancer Therapeutics\u00a0and was co-authored by researchers from the Fred Hutchinson Cancer Research Center, SEngine Precision Medicine, Weill Cornell Medicine, and the University of Washington. Ovarian clear cell carcinoma, a relatively uncommon subtype of ovarian cancer, has historically been treated with the same &hellip; Continue reading \"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T13:03:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics","datePublished":"2021-04-05T13:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/"},"wordCount":672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/","name":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=","datePublished":"2021-04-05T13:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTI0MyM0MTA1MTQzIzIxOTc1MjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicines-paris-test-identifies-novel-therapeutic-options-for-ovarian-clear-cell-carcinoma-in-study-published-in-aacrs-molecular-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SEngine Precision Medicine\u2019s PARIS\u00ae Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR\u2019s Molecular Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470805"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470805\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}